ING Parcom acquires Unither

4 December 2006

Unither, a French contract producer of pharmaceutical products, especially serums and anti-asthmatics in sterile unitary dosage form, has been acquired by ING Parcom Equity, the French arm of the Netherlands investment fund Parcom. ING now has a stake in the French firm of a little over 50% of capital and over 30% on the management side. Unither was set up in 1993 by its current director general Patrick Colin, based on the acquisition of a plant owned by Sanofi-Aventis. Its annual sales are around 76.0 million euros ($100.2 million).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight